Compounds > enantio-PAF C-16
Page last updated: 2024-12-04

enantio-PAF C-16

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID2499
CHEMBL ID17935
CHEBI ID184170
SCHEMBL ID2734461

Synonyms (25)

Synonym
gtpl1834
enantio paf c-16
(2-acetyloxy-3-hexadecoxypropyl) 2-trimethylazaniumylethyl phosphate
enantio platelet-activating factor c-16
L000911
enantio-paf c-16
CHEMBL17935
(2-acetyloxy-3-hexadecoxypropyl) 2-(trimethylazaniumyl)ethyl phosphate
CHEBI:184170
1-o-palmityl-2-acetyl-rac-glycero-3-phosphocholine
FT-0614428
2-(acetyloxy)-3-(hexadecyloxy)propyl 2-(trimethylammonio)ethyl phosphate
SCHEMBL2734461
1-o-hexadecyl-2-acetyl-rac-glycero-3-phosphocholine
J-003694
enantio-paf (c)
3-o-hexadecyl-2-o-acetyl-sn-glycero-1-phosphocholine
DTXSID90922585
2-(acetyloxy)-3-(hexadecyloxy)propyl 2-(trimethylazaniumyl)ethyl phosphate
1-o-hexadecyl-2-acetyl-rac-glycero-3-phosphochline
2-acetoxy-3-(hexadecyloxy)propyl 2-(trimethylammonio)ethyl phosphate
Q27077181
enantio-paf (c16)
beta -acetyl- gamma -o-alkyl-l- alpha -phosphatidylcholine
pc o-16:0_2:0
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
alkylacylglycero-3-phosphocholineA glycerophosphocholine that is glycero-3-phosphocholine carrying one alkyl and one acyl group in unspecified positions. Major species at pH 7.3.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (38)

Assay IDTitleYearJournalArticle
AID175321Compound is evaluated for hypotensive activity in anesthetized rat (in vivo)1987Journal of medicinal chemistry, May, Volume: 30, Issue:5
Structure-activity relationship in PAF-acether. 3. Hydrophobic contribution to agonistic activity.
AID173953Tested for the dose needed to decrease mean arterial blood pressure (MABP) 50 mmHg in male rats, iv1984Journal of medicinal chemistry, Sep, Volume: 27, Issue:9
Analogues of platelet activating factor (PAF). 1. Some modifications of the alkoxy chain.
AID74005Compound was evaluated for in vivo bronchoconstriction in anesthetized guinea pig (3 cm H2O)1987Journal of medicinal chemistry, May, Volume: 30, Issue:5
Structure-activity relationship in PAF-acether. 3. Hydrophobic contribution to agonistic activity.
AID173374Hypotensive activity in spontaneously hypertensive rat expressed as decrease in systolic BP at 3 mg/kg, po1986Journal of medicinal chemistry, Oct, Volume: 29, Issue:10
Molecular design toward biologically significant compounds based on platelet activating factor: a highly selective agonist as a potential antihypertensive agent.
AID173545Compound was evaluated in spontaneous hypertensive rats (SHR) for the intravenous dose required to decrease mean arterial blood pressure (MABP) 50 mmHg1986Journal of medicinal chemistry, Jul, Volume: 29, Issue:7
Analogues of platelet activating factor. 5. Multiple oxygen substitution of the alkoxy chain.
AID89285Desensitizing action on human PMN degranulation response, in the presence of FMLP (17 nM) at the dose of 8 nM1985Journal of medicinal chemistry, Jan, Volume: 28, Issue:1
Facile synthesis of platelet-activating factor and racemic analogues containing unsaturation in the sn-1-alkyl chain.
AID89290Desensitizing action on human PMN degranulation response, in the presence of PAF (200 nM) at the dose of 8 nM1985Journal of medicinal chemistry, Jan, Volume: 28, Issue:1
Facile synthesis of platelet-activating factor and racemic analogues containing unsaturation in the sn-1-alkyl chain.
AID167864Relative activity against platelet aggregation in [14C]5-HT preloaded rabbit platelet for 2 mins1986Journal of medicinal chemistry, Oct, Volume: 29, Issue:10
Molecular design toward biologically significant compounds based on platelet activating factor: a highly selective agonist as a potential antihypertensive agent.
AID173373Hypotensive activity in spontaneously hypertensive rat expressed as decrease in systolic BP at 25 mg/kg, po1986Journal of medicinal chemistry, Oct, Volume: 29, Issue:10
Molecular design toward biologically significant compounds based on platelet activating factor: a highly selective agonist as a potential antihypertensive agent.
AID77533Effective dose for relaxation of guinea pig taenia coli strips1989Journal of medicinal chemistry, Jun, Volume: 32, Issue:6
Darmstoff analogues. 3. Actions of choline esters of acetal phosphatidic acids on visceral smooth muscle.
AID165609Compound was tested in vitro for its ability to aggregate platelet-rich plasma (PRP) in rabbit1987Journal of medicinal chemistry, May, Volume: 30, Issue:5
Structure-activity relationship in PAF-acether. 3. Hydrophobic contribution to agonistic activity.
AID230123Ratio of platelet activation to antihypertension1986Journal of medicinal chemistry, Oct, Volume: 29, Issue:10
Molecular design toward biologically significant compounds based on platelet activating factor: a highly selective agonist as a potential antihypertensive agent.
AID165610Compound was tested in vitro for its ability to aggregate washed rabbit platelets (WP)1987Journal of medicinal chemistry, May, Volume: 30, Issue:5
Structure-activity relationship in PAF-acether. 3. Hydrophobic contribution to agonistic activity.
AID189552Antihypertensive activity using C16-PAF in rat at a doses ranging from 1-10 nmol/kg iv1986Journal of medicinal chemistry, Oct, Volume: 29, Issue:10
Molecular design toward biologically significant compounds based on platelet activating factor: a highly selective agonist as a potential antihypertensive agent.
AID161774Maximum platelet aggregation units at 1.3*10e-5 molar concentration was determined.1985Journal of medicinal chemistry, Sep, Volume: 28, Issue:9
Analogues of platelet activating factor (PAF). 2. Some modifications of the glycerine backbone.
AID173774Intravenous dose required to decrease mean arterial blood pressure (MABP) 50 mm Hg1986Journal of medicinal chemistry, Mar, Volume: 29, Issue:3
Analogues of platelet activating factor. 4. Some modifications of the phosphocholine moiety.
AID165636Relative aggregant activity in rabbit platelets was determined1987Journal of medicinal chemistry, May, Volume: 30, Issue:5
Structure-activity relationship in PAF-acether. 3. Hydrophobic contribution to agonistic activity.
AID681337TP_TRANSPORTER: Western blot, HK-2 cells2002Toxicology and applied pharmacology, Sep-01, Volume: 183, Issue:2
Influence of different chemicals on MDR-1 P-glycoprotein expression and activity in the HK-2 proximal tubular cell line.
AID161918The maximum aggregation response observed at 6.8e-6 M concentration of the compound1986Journal of medicinal chemistry, Mar, Volume: 29, Issue:3
Analogues of platelet activating factor. 4. Some modifications of the phosphocholine moiety.
AID233534The ratio of (MABP / Platelet EC 50) x 1001986Journal of medicinal chemistry, Mar, Volume: 29, Issue:3
Analogues of platelet activating factor. 4. Some modifications of the phosphocholine moiety.
AID176023Tested for the molar concentration required to cause 50% of maximum aggregation1984Journal of medicinal chemistry, Sep, Volume: 27, Issue:9
Analogues of platelet activating factor (PAF). 1. Some modifications of the alkoxy chain.
AID160092Compound was evaluated in rabbit-platelet rich plasma (PRP) for the maximum aggregation response observed 6.8*10e-6 molar concentration1986Journal of medicinal chemistry, Jul, Volume: 29, Issue:7
Analogues of platelet activating factor. 5. Multiple oxygen substitution of the alkoxy chain.
AID230049Ratio of MABP to that of platelet EC50 of the compound.1985Journal of medicinal chemistry, Sep, Volume: 28, Issue:9
Analogues of platelet activating factor (PAF). 2. Some modifications of the glycerine backbone.
AID173370Hypotensive activity in spontaneously hypertensive rat expressed as decrease in systolic BP at 0.3mg/kg, po1986Journal of medicinal chemistry, Oct, Volume: 29, Issue:10
Molecular design toward biologically significant compounds based on platelet activating factor: a highly selective agonist as a potential antihypertensive agent.
AID160090Compound was evaluated in rabbit-platelet rich plasma (PRP) for the molar concentration required to produce 50% of maximum aggregation1986Journal of medicinal chemistry, Jul, Volume: 29, Issue:7
Analogues of platelet activating factor. 5. Multiple oxygen substitution of the alkoxy chain.
AID161909Effective concentration required to produce 50% of maximum aggregation of platelets1986Journal of medicinal chemistry, Mar, Volume: 29, Issue:3
Analogues of platelet activating factor. 4. Some modifications of the phosphocholine moiety.
AID161767Effective concentration required to produce 50% of the maximum platelet aggregation using rabbit platelet-rich plasma was determined.1985Journal of medicinal chemistry, Sep, Volume: 28, Issue:9
Analogues of platelet activating factor (PAF). 2. Some modifications of the glycerine backbone.
AID231444Ratio = (MABP / platelet EC50 ) x 10 E -81984Journal of medicinal chemistry, Sep, Volume: 27, Issue:9
Analogues of platelet activating factor (PAF). 1. Some modifications of the alkoxy chain.
AID231374Ratio value is (MAPB/platelet EC50)*10e-81986Journal of medicinal chemistry, Jul, Volume: 29, Issue:7
Analogues of platelet activating factor. 5. Multiple oxygen substitution of the alkoxy chain.
AID681385TP_TRANSPORTER: RT-PCR in HK-2 cell2002Toxicology and applied pharmacology, Sep-01, Volume: 183, Issue:2
Influence of different chemicals on MDR-1 P-glycoprotein expression and activity in the HK-2 proximal tubular cell line.
AID89292Effective dose for lysozyme release in human PMN was measured1985Journal of medicinal chemistry, Jan, Volume: 28, Issue:1
Facile synthesis of platelet-activating factor and racemic analogues containing unsaturation in the sn-1-alkyl chain.
AID173746Hypotensive activity of compound was determined in hypertensive rats, as dose required to decrease the mean arterial blood pressure 50 mmHg was determined1985Journal of medicinal chemistry, Sep, Volume: 28, Issue:9
Analogues of platelet activating factor (PAF). 2. Some modifications of the glycerine backbone.
AID75944Compound was evaluated for in vivo thrombocytopenia effect in anesthetized guinea pig1987Journal of medicinal chemistry, May, Volume: 30, Issue:5
Structure-activity relationship in PAF-acether. 3. Hydrophobic contribution to agonistic activity.
AID167456Effective dose for [14C]5-HT release in prelabeled rabbit platelets was measured1985Journal of medicinal chemistry, Jan, Volume: 28, Issue:1
Facile synthesis of platelet-activating factor and racemic analogues containing unsaturation in the sn-1-alkyl chain.
AID167753Compound did not aggregate rabbit platelet at concentration of 1.8E-5 M1985Journal of medicinal chemistry, Sep, Volume: 28, Issue:9
Analogues of platelet activating factor. 3. Replacement of the phosphate moiety with a sulfonylbismethylene group.
AID167156Tested for maximum aggregation units at specified molar concentration1984Journal of medicinal chemistry, Sep, Volume: 27, Issue:9
Analogues of platelet activating factor (PAF). 1. Some modifications of the alkoxy chain.
AID170649Effect on mean arterial blood pressure in SHR rat at the dose of 0.3 mg/kg i.v.1985Journal of medicinal chemistry, Sep, Volume: 28, Issue:9
Analogues of platelet activating factor. 3. Replacement of the phosphate moiety with a sulfonylbismethylene group.
AID1346403Human PAF receptor (Platelet-activating factor receptor)1995Journal of immunological methods, Oct-26, Volume: 186, Issue:2
A radioreceptor binding assay for platelet-activating factor (PAF) using membranes from CHO cells expressing human PAF receptor.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (11)

TimeframeStudies, This Drug (%)All Drugs %
pre-19909 (81.82)18.7374
1990's1 (9.09)18.2507
2000's1 (9.09)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.68

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index11.68 (24.57)
Research Supply Index2.48 (2.92)
Research Growth Index4.16 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (11.68)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other11 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
3-methylcholanthrene
Methylcholanthrene: A carcinogen that is often used in experimental cancer studies.. 3-methylcholanthrene : A pentacyclic ortho- and peri-fused polycyclic arene consisting of a dihydrocyclopenta[ij]tetraphene ring system with a methyl substituent at the 3-position.		2.0110ortho- and peri-fused polycyclic arenearyl hydrocarbon receptor agonist;
carcinogenic agent
1-0-octadecyl 2-0-acetyl sn-glycero-3-phosphorylcholine
1-0-octadecyl 2-0-acetyl sn-glycero-3-phosphorylcholine: reported to have same biological activity as natural PAF-acether; RN given refers to parent cpd without isomeric designation		2.8840
verapamil
Verapamil: A calcium channel blocker that is a class IV anti-arrhythmia agent.. verapamil : A racemate comprising equimolar amounts of dexverapamil and (S)-verapamil. An L-type calcium channel blocker of the phenylalkylamine class, it is used (particularly as the hydrochloride salt) in the treatment of hypertension, angina pectoris and cardiac arrhythmia, and as a preventive medication for migraine.. 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile : A tertiary amino compound that is 3,4-dimethoxyphenylethylamine in which the hydrogens attached to the nitrogen are replaced by a methyl group and a 4-cyano-4-(3,4-dimethoxyphenyl)-5-methylhexyl group.		2.0110aromatic ether;
nitrile;
polyether;
tertiary amino compound
cimetidine
Cimetidine: A histamine congener, it competitively inhibits HISTAMINE binding to HISTAMINE H2 RECEPTORS. Cimetidine has a range of pharmacological actions. It inhibits GASTRIC ACID secretion, as well as PEPSIN and GASTRIN output.. cimetidine : A member of the class of guanidines that consists of guanidine carrying a methyl substituent at position 1, a cyano group at position 2 and a 2-{[(5-methyl-1H-imidazol-4-yl)methyl]sulfanyl}ethyl group at position 3. It is a H2-receptor antagonist that inhibits the production of acid in stomach.		2.0110aliphatic sulfide;
guanidines;
imidazoles;
nitrile		adjuvant;
analgesic;
anti-ulcer drug;
H2-receptor antagonist;
P450 inhibitor
trimethoprim
Trimethoprim: A pyrimidine inhibitor of dihydrofolate reductase, it is an antibacterial related to PYRIMETHAMINE. It is potentiated by SULFONAMIDES and the TRIMETHOPRIM, SULFAMETHOXAZOLE DRUG COMBINATION is the form most often used. It is sometimes used alone as an antimalarial. TRIMETHOPRIM RESISTANCE has been reported.. trimethoprim : An aminopyrimidine antibiotic whose structure consists of pyrimidine 2,4-diamine and 1,2,3-trimethoxybenzene moieties linked by a methylene bridge.		2.0110aminopyrimidine;
methoxybenzenes		antibacterial drug;
diuretic;
drug allergen;
EC 1.5.1.3 (dihydrofolate reductase) inhibitor;
environmental contaminant;
xenobiotic
aldosterone
[no description available]		2.011011beta-hydroxy steroid;
18-oxo steroid;
20-oxo steroid;
21-hydroxy steroid;
3-oxo-Delta(4) steroid;
C21-steroid hormone;
mineralocorticoid;
primary alpha-hydroxy ketone;
steroid aldehyde		human metabolite;
mouse metabolite
2-acetylaminofluorene
2-Acetylaminofluorene: A hepatic carcinogen whose mechanism of activation involves N-hydroxylation to the aryl hydroxamic acid followed by enzymatic sulfonation to sulfoxyfluorenylacetamide. It is used to study the carcinogenicity and mutagenicity of aromatic amines.		2.01102-acetamidofluorenesantimitotic;
carcinogenic agent;
epitope;
mutagen
web 2086
WEB 2086: structure given in first source; PAF antagonist		1.9810organonitrogen heterocyclic compound;
organosulfur heterocyclic compound
1-hexadecyl-2-acetyl-glycero-3-phosphocholine
Platelet Activating Factor: A phospholipid derivative formed by PLATELETS; BASOPHILS; NEUTROPHILS; MONOCYTES; and MACROPHAGES. It is a potent platelet aggregating agent and inducer of systemic anaphylactic symptoms, including HYPOTENSION; THROMBOCYTOPENIA; NEUTROPENIA; and BRONCHOCONSTRICTION.. 2-O-acetyl-1-O-hexadecyl-sn-glycero-3-phosphocholine : A 2-acetyl-1-alkyl-sn-glycero-3-phosphocholine betaine which has hexadecyl as the alkyl group. PAF is a potent phospholipid activator and mediator of many leukocyte functions, including platelet aggregation, inflammation, and anaphylaxis.		1.98102-acetyl-1-alkyl-sn-glycero-3-phosphocholineantihypertensive agent;
beta-adrenergic antagonist;
bronchoconstrictor agent;
hematologic agent;
vasodilator agent
1-0-octadecyl 2-0-acetyl sn-glycero-3-phosphorylcholine
2-O-acetyl-1-O-octadecyl-sn-glycero-3-phosphocholine : A 2-acetyl-1-alkyl-sn-glycero-3-phosphocholine betaine which has octadecyl as the alkyl group. PAF is a potent phospholipid activator and mediator of many leukocyte functions, including platelet aggregation, inflammation, and anaphylaxis.		1.97102-acetyl-1-alkyl-sn-glycero-3-phosphocholineantihypertensive agent;
beta-adrenergic antagonist;
bronchoconstrictor agent;
hematologic agent;
vasodilator agent
cyclosporine
ramihyphin A: one of the metabolites produced by Fusarium sp. S-435; RN given refers to cpd with unknown MF		2.0110homodetic cyclic peptideanti-asthmatic drug;
anticoronaviral agent;
antifungal agent;
antirheumatic drug;
carcinogenic agent;
dermatologic drug;
EC 3.1.3.16 (phosphoprotein phosphatase) inhibitor;
geroprotector;
immunosuppressive agent;
metabolite
ConditionIndicatedRelationship StrengthStudiesTrials
Muscle Contraction
A process leading to shortening and/or development of tension in muscle tissue. Muscle contraction occurs by a sliding filament mechanism whereby actin filaments slide inward among the myosin filaments.		01.9710
Constriction, Pathological
[description not available]		01.9710
Thrombopenia
[description not available]		01.9710
Constriction, Pathologic
The condition of an anatomical structure's being constricted beyond normal dimensions.		01.9710
Thrombocytopenia
A subnormal level of BLOOD PLATELETS.		01.9710